Scpharmaceuticals Stock Revenue
| SCPH Stock | USD 3.74 0.14 3.89% |
Scpharmaceuticals fundamentals help investors to digest information that contributes to Scpharmaceuticals' financial success or failures. It also enables traders to predict the movement of Scpharmaceuticals Stock. The fundamental analysis module provides a way to measure Scpharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Scpharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 13.6 M | 14.3 M |
Scpharmaceuticals | Revenue |
Scpharmaceuticals Company Revenue Analysis
Scpharmaceuticals' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Scpharmaceuticals Revenue | 13.59 M |
Most of Scpharmaceuticals' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Scpharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Scpharmaceuticals
Projected quarterly revenue analysis of Scpharmaceuticals provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Scpharmaceuticals match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Scpharmaceuticals' stock price.
Scpharmaceuticals Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Scpharmaceuticals is extremely important. It helps to project a fair market value of Scpharmaceuticals Stock properly, considering its historical fundamentals such as Revenue. Since Scpharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Scpharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Scpharmaceuticals' interrelated accounts and indicators.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Scpharmaceuticals Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Scpharmaceuticals reported 13.59 M of revenue. This is 99.82% lower than that of the Pharmaceuticals sector and 98.17% lower than that of the Health Care industry. The revenue for all United States stocks is 99.86% higher than that of the company.
Scpharmaceuticals Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Scpharmaceuticals' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Scpharmaceuticals could also be used in its relative valuation, which is a method of valuing Scpharmaceuticals by comparing valuation metrics of similar companies.Scpharmaceuticals is currently under evaluation in revenue category among its peers.
Scpharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Scpharmaceuticals from analyzing Scpharmaceuticals' financial statements. These drivers represent accounts that assess Scpharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Scpharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 105.3M | 130.0M | 137.3M | 203.3M | 241.5M | 253.6M | |
| Enterprise Value | 52.7M | 44.9M | 80.7M | 169.6M | 234.9M | 246.7M |
Scpharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Scpharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Scpharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Scpharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Scpharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Scpharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Scpharmaceuticals' value.| Shares | Tejara Capital Ltd | 2024-06-30 | 704.7 K | State Street Corp | 2024-06-30 | 648.3 K | Geode Capital Management, Llc | 2024-09-30 | 643.3 K | Rice Hall James & Associates, Llc | 2024-09-30 | 621.7 K | Citadel Advisors Llc | 2024-09-30 | 526 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 442.6 K | Stonepine Capital Management Llc | 2024-06-30 | 421.7 K | Walleye Trading Advisors, Llc | 2024-06-30 | 374.4 K | Bank Of Montreal | 2024-06-30 | 351.8 K | Orbimed Advisors, Llc | 2024-06-30 | 5.6 M | Aigh Capital Management, Llc | 2024-09-30 | 4.1 M |
Scpharmaceuticals Fundamentals
| Return On Equity | -1.67 | ||||
| Return On Asset | -0.42 | ||||
| Profit Margin | (2.65) % | ||||
| Operating Margin | (1.81) % | ||||
| Current Valuation | 141.16 M | ||||
| Shares Outstanding | 50.04 M | ||||
| Shares Owned By Insiders | 8.43 % | ||||
| Shares Owned By Institutions | 80.30 % | ||||
| Number Of Shares Shorted | 5.46 M | ||||
| Price To Book | 5.87 X | ||||
| Price To Sales | 6.18 X | ||||
| Revenue | 13.59 M | ||||
| EBITDA | (46.06 M) | ||||
| Net Income | (54.81 M) | ||||
| Cash And Equivalents | 55.85 M | ||||
| Cash Per Share | 2.04 X | ||||
| Total Debt | 40.27 M | ||||
| Debt To Equity | 0.32 % | ||||
| Current Ratio | 3.72 X | ||||
| Book Value Per Share | 1.03 X | ||||
| Cash Flow From Operations | (59.24 M) | ||||
| Short Ratio | 12.92 X | ||||
| Earnings Per Share | (1.95) X | ||||
| Target Price | 18.0 | ||||
| Number Of Employees | 135 | ||||
| Beta | 0.14 | ||||
| Market Capitalization | 187.15 M | ||||
| Total Asset | 94.48 M | ||||
| Retained Earnings | (281.35 M) | ||||
| Working Capital | 79.8 M | ||||
| Net Asset | 94.48 M |
About Scpharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Scpharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Scpharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Scpharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Scpharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Scpharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Scpharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Scpharmaceuticals Stock:Check out Scpharmaceuticals Piotroski F Score and Scpharmaceuticals Altman Z Score analysis. For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Scpharmaceuticals. If investors know Scpharmaceuticals will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Scpharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.95) | Revenue Per Share 0.741 | Quarterly Revenue Growth 1.641 | Return On Assets (0.42) | Return On Equity (1.67) |
The market value of Scpharmaceuticals is measured differently than its book value, which is the value of Scpharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Scpharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Scpharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Scpharmaceuticals' market value can be influenced by many factors that don't directly affect Scpharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Scpharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Scpharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Scpharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.